Core Insights - Heartflow, Inc. is set to present new data on the clinical and economic value of its AI-powered Heartflow Plaque Analysis at the AHA Scientific Sessions 2025, emphasizing its role in predicting long-term cardiovascular outcomes [1][2]. Company Developments - Heartflow will showcase seven abstracts at the AHA Scientific Sessions, reinforcing the scientific foundation for its Plaque Analysis as a significant advancement in cardiovascular risk prediction and personalized treatment [3]. - The company continues to invest in clinical research to validate its Plaque Analysis technology, which aids cardiologists in personalizing treatment plans using non-invasive methods [4]. Research Highlights - Key presentations at the AHA will include studies on coronary CT angiography as a predictor of death and myocardial infarction, improvements in cardiovascular risk assessment, and the cost-effectiveness of AI-enabled coronary plaque analysis [5][8]. - The FISH&CHIPS study, which will be presented by Dr. Timothy Fairbairn, focuses on plaque volume burden and its implications for cardiovascular risk [2][6]. Technology and Impact - Heartflow's technology utilizes AI to convert coronary CTA images into personalized 3D heart models, providing actionable insights into plaque characteristics and their impact on blood flow [14]. - The company has been adopted by over 1,400 institutions globally and has supported the management of nearly 500,000 patients, demonstrating its significant impact on cardiovascular care [13][14].